[
  {
    "ts": null,
    "headline": "IDEXX Laboratories Inc. stock outperforms competitors on strong trading day",
    "summary": "IDEXX Laboratories Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=5fea87fbd6bd83491270a2f669e0395eb205d1228c5bb29bf02d7ff002b20413",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745340900,
      "headline": "IDEXX Laboratories Inc. stock outperforms competitors on strong trading day",
      "id": 134081508,
      "image": "",
      "related": "IDXX",
      "source": "MarketWatch",
      "summary": "IDEXX Laboratories Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=5fea87fbd6bd83491270a2f669e0395eb205d1228c5bb29bf02d7ff002b20413"
    }
  },
  {
    "ts": null,
    "headline": "Idexx Laboratories price target lowered to $475 from $535 at BofA",
    "summary": "BofA lowered the firm’s price target on Idexx Laboratories (IDXX) to $475 from $535 and keeps a Neutral rating on the shares. Heading into Q1 earnings, the firm says sentiment on its animal health coverage “skews generally negative,” with a number of broader market and company-specific headwinds. The firm sees limited near-term catalysts to drive estimates higher beyond improved foreign exchange rates, so it thinks shares will remain capped near current levels, the analyst added in a preview for",
    "url": "https://finnhub.io/api/news?id=af6223bfc13bc1453b2b65b052af91dcb8c0084a9caa08c338a494913681e524",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745335547,
      "headline": "Idexx Laboratories price target lowered to $475 from $535 at BofA",
      "id": 134039400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IDXX",
      "source": "Yahoo",
      "summary": "BofA lowered the firm’s price target on Idexx Laboratories (IDXX) to $475 from $535 and keeps a Neutral rating on the shares. Heading into Q1 earnings, the firm says sentiment on its animal health coverage “skews generally negative,” with a number of broader market and company-specific headwinds. The firm sees limited near-term catalysts to drive estimates higher beyond improved foreign exchange rates, so it thinks shares will remain capped near current levels, the analyst added in a preview for",
      "url": "https://finnhub.io/api/news?id=af6223bfc13bc1453b2b65b052af91dcb8c0084a9caa08c338a494913681e524"
    }
  }
]